ReviewCurrent rheumatology reports2002
Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis.
Review in Current rheumatology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 212 citations in OpenAlex.
- Human amniotic membrane modulates collagen production and deposition in vitro.Scientific reports · 2024Article
- A new lymphedema treatment using pyro-drive jet injection.Human cell · 2024Article
- Anoctamin-1 is induced by TGF-β and contributes to lung myofibroblast differentiation.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Anoctamin-1 is induced by TGF-beta and contributes to lung myofibroblast differentiation.bioRxiv : the preprint server for biology · 2023Article
- CCN2/CTGF tip the balance of growth factors towards TGF-β2 in primary open-angle glaucoma.Frontiers in molecular biosciences · 2023Article
- NF-кB c-Rel modulates pre-fibrotic changes in human fibroblasts.Archives of dermatological research · 2022Article
- Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiological reviews · 2022Review
- CCN2/CTGF-A Modulator of the Optic Nerve Head Astrocyte.Frontiers in cell and developmental biology · 2022Article
- The Immunogenetics of Systemic Sclerosis.Advances in experimental medicine and biology · 2022Article
- The Immunogenetics of Morphea and Lichen Sclerosus.Advances in experimental medicine and biology · 2022Review
- Dehydrated Human Amniotic Membrane Inhibits Myofibroblast Contraction through the Regulation of the TGFβ‒SMAD Pathway In Vitro.JID innovations : skin science from molecules to population health · 2021Article
- Biomedical and Tissue Engineering Strategies to Control Foreign Body Reaction to Invasive Neural Electrodes.Frontiers in bioengineering and biotechnology · 2021Review
- Article
- A CTGF-YAP Regulatory Pathway Is Essential for Angiogenesis and Barriergenesis in the Retina.iScience · 2020Article
- Anti-fibrotic effects of tannic acid through regulation of a sustained TGF-beta receptor signaling.Respiratory research · 2019Article
- Calcified decellularized arterial scaffolds impact vascular smooth muscle cell transformation via downregulating α-SMA expression and upregulating OPN expression.Experimental and therapeutic medicine · 2019Article
- Cells, soluble factors and matrix harmonically play the concert of allograft integration.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2019Review
- Allograft tendons are a safe and effective option for revision ACL reconstruction: a clinical review.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2019Review
- Sustained Smad2 Phosphorylation Is Required for Myofibroblast Transformation in Response to TGF-β.American journal of respiratory cell and molecular biology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Connective tissue fibrosis is the final common pathogenic process for almost all forms of chronic tissue injury. Whether caused by vascular dysfunction, inflammation, metabolic injury, trauma, or environmental agents, once initiated the fibrogenic process results in the progressive replacement of the normal tissue architecture with fibrotic lesions that eventually lead to organ compromise and failure. Fibrosis can be considered as a dysregulation in the normal tissue repair mechanism, resulting in severe tissue scarring. Fibrosis appears to be a consequence of linked processes, including the proliferation of resident fibroblast cell types, the increased production and deposition of extracellular matrix components, and the transition of fibroblasts into cells exhibiting a myofibroblast phenotype. Although transforming growth factor-beta (TGF beta) has long been regarded as a pivotal growth factor in the formation and maintenance of connective tissues and as a major driving influence in many progressive fibrotic diseases, attention has focused recently on the role of connective tissue growth factor (CTGF) in fibrosis. CTGF is selectively and rapidly induced in mesenchymally derived cells by the action of TGF beta. CTGF expression is increased in many fibrosing diseases. In addition, increasing evidence from in vivo and in vitro models of tissue remodeling and fibrosis suggest that CTGF may represent a downstream effector molecule of the profibrotic activities of TGF beta in the maintenance and repair of connective tissues and within fibrotic disease settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.